On November 11, 2023, Lizhu Pharmaceutical (HKG: 1513) announced a strategic shift in its plans for its subsidiary, Lizhu Reagent. The company has decided to terminate its initial plan to spin off Lizhu Reagent for a listing on the Shenzhen Stock Exchange’s ChiNext board. Instead, it will file for a listing on the National Equities Exchange and Quotations (NEEQ) board, which is designed for small and medium-sized enterprises. Following the NEEQ listing, Lizhu Reagent intends to pursue a Beijing Stock Exchange listing at an opportune time, contingent on the future capital market environment and the company’s strategic development needs.
Lizhu Reagent’s Background and Specialization
Established in 1989 with a registered capital of RMB 400 million, Lizhu Reagent is a company dedicated to the research and development, production, and sale of diagnostic reagents and equipment. Through years of dedicated cultivation and development, Lizhu Reagent has established a multi-dimensional technology platform that encompasses enzyme-linked immunity, colloidal gold rapid detection, chemiluminescence, multiple liquid chip technologies, and nucleic acid testing, among other fields.
Market Influence and Product Leadership
Lizhu Reagent has gained strong market influence in the areas of respiratory infections and infectious diseases, with some of its products holding leading positions in the Chinese market. The company’s diagnostic reagents and equipment are crucial tools in drug concentration monitoring and other critical healthcare applications.- Flcube.com
